Therapeutic drug monitoring of adalimumab for dose optimization during maintenance therapy in patients with ulcerative colitis: real-world data.

Ulcerative colitis (UC) is a chronic inflammatory disease that primarily affects the colon. Tumor necrosis factor-α inhibitors (like adalimumab) are effective agents for UC. However, loss of response may occur. Proactive therapeutic drug monitoring involves measuring drug levels at regular intervals in patients in remission to maintain therapeutic concentrations and potentially prevent loss of response.